XML 107 R80.htm IDEA: XBRL DOCUMENT v3.24.0.1
Variable Interest Entities - Additional Information (Details)
shares in Millions
1 Months Ended 12 Months Ended
Sep. 30, 2021
USD ($)
shares
Mar. 31, 2021
USD ($)
shares
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
acquisition
shares
Dec. 31, 2021
USD ($)
Variable Interest Entity [Line Items]          
Variable interest entity ownership percentage       100.00%  
Number of ventures formed | acquisition       2  
Total Zymergen purchase price consideration     $ 0 $ 19,912,000 $ 8,760,000
(Loss) gain on deconsolidation of subsidiaries     $ (42,502,000) 31,889,000 $ 0
Series A Preferred Stock          
Variable Interest Entity [Line Items]          
Shares sold (in shares) | shares   1.8      
Total Zymergen purchase price consideration   $ 19,500,000   57,100,000  
Parent          
Variable Interest Entity [Line Items]          
Equity interest     70.00%    
Control of board of directors     100.00%    
Non- Controlling Interest          
Variable Interest Entity [Line Items]          
Equity interest     30.00%    
Convertible Promissory Notes | Member Units          
Variable Interest Entity [Line Items]          
Variable interest entity, financial or other support       10,000,000.0  
Verb And Ayana          
Variable Interest Entity [Line Items]          
(Loss) gain on deconsolidation of subsidiaries       31,900,000  
Ayana Bio LLC          
Variable Interest Entity [Line Items]          
Equity method investment       16,000,000.0  
Investment company, financial support to investee, amount       0  
Carrying value of equity method investment       $ 0  
Ayana Bio LLC | Series A Preferred Stock          
Variable Interest Entity [Line Items]          
Shares sold (in shares) | shares 9.0        
Total Zymergen purchase price consideration $ 30,000,000        
Ayana Bio LLC | License          
Variable Interest Entity [Line Items]          
Common units (in shares) | shares       9.0  
Verb          
Variable Interest Entity [Line Items]          
Equity method investment       $ 15,900,000  
Carrying value of equity method investment       $ 0  
Verb | Series A Preferred Stock          
Variable Interest Entity [Line Items]          
Shares sold (in shares) | shares 9.0        
Total Zymergen purchase price consideration $ 30,000,000        
Verb | License          
Variable Interest Entity [Line Items]          
Common units (in shares) | shares       9.0  
Verb | Maximum          
Variable Interest Entity [Line Items]          
Carrying value of equity method investment       $ 0